
Sign up to save your podcasts
Or


What if the medications that were supposed to fix obesity turned out to be just the beginning of the story? After decades of studying weight loss, Holly and Jim thought they had seen it all. Then a new class of medications arrived and overturned some of their most basic assumptions.
In this episode, each of them brings five things that genuinely surprised them about the GLP-1 era. Some are about the science, some are about what they see in patients, and some are about what these medications were expected to solve but haven't. Two longtime experts admit what they got wrong, what they're still puzzling over, and where they disagree. Join Holly and Jim for a candid look at where obesity treatment stands now, and why they believe the most interesting questions are only just being asked.
Discussed on the episode:
You’ve hit your goal weight, or you’re close. So why doesn’t life feel as different as you expected? For many people, the number on the scale was never really the point. It was a stand-in for feeling confident, joining in, and finally enjoying life.
Today’s weight loss medications are helping people lose weight that once felt out of reach. A large new BMJ analysis asked whether quality of life is keeping pace, and the answer may make you rethink what success means. Join Holly and Jim as they dig into the findings, why feeling better and weighing less don’t always move together, and share what they’d do about it.
You’ll leave with practical, doable steps you can start now, long before you reach your goal weight. Press play to find out what to work on alongside your weight loss.
Discussed on the episode:
Resources mentioned:
Your friend just started semaglutide. She got it online; it's "compounded," it has B12 in it, and it's only $199 a month. Sounds like a great deal, right? But what exactly is in that vial, who made it, and how much are you supposed to take? More and more people are facing these questions every day, and most of us don't know how to answer them.
Join Holly and Jim as they welcome not one, not two, but three guests for the very first time: Misty Gaddis, pharmacy manager of medication compounding safety; Jessica Pescatore, clinical director of the Alabama Poison Information Center; and Richelle Chambliss, a clinical pharmacist who supports UAB's weight management clinics. Together, they pull back the curtain on compounded GLP-1s and share what your pharmacist wants you to know about weight loss medications, from dosing and side effects to insurance, access, and stopping and restarting. You'll come away with practical questions to ask and red flags to watch for before you inject anything.
Discussed on the episode:
New obesity medications can now produce weight loss once thought impossible without surgery. That success is forcing doctors to ask a question they never had to face before: what if a treatment doesn't know when to stop?
Join Holly and Jim as they unpack six new questions these next-generation drugs have raised in obesity medicine. Using a relatable patient case, they explore the difference between losing the maximum amount of weight and losing the optimal amount, and why those two things are no longer the same. You'll also hear where lifestyle fits into treatment now, what "success" really means when the scale isn't the whole story, and why the answers may ultimately come down to a conversation between patient and provider.
Discussed on the episode:
If losing weight made movement easier, wouldn’t you naturally start moving more? It’s the kind of assumption that feels almost too obvious to question: shed 40 or 50 pounds, and your knees stop aching, the stairs get easier, and you’re out there living more. Holly and Jim certainly believed it. But in the age of GLP-1 medications, where rapid, substantial weight loss is now common, does this assumption still hold up?
In this episode, Holly and Jim put that belief to the test with real data. Diving into three separate studies (including brand-new, cutting-edge research), they explore what happens to physical activity levels once people start losing weight on GLP-1s. The results might surprise you, and as Jim warns early on, they might leave you feeling a little deflated too. But stick around, because Holly and Jim don’t just deliver the bad news; they explain why it matters and what you can actually do about it.
Discussed on the episode
Everyone knows GLP-1 medications help people eat less. But does eating less actually mean eating better? It’s a question the weight loss field never really had to ask before, and the answer might surprise you.
Join Holly and Jim as they dig into three GLP-1 studies looking at what people are actually eating. You’ll hear the real numbers behind diet quality, protein intake, and nutrient gaps on these medications, plus what it means for anyone currently taking (or considering) a GLP-1. Holly and Jim also share five practical tips to help ensure your diet works as hard as your medication is.
Discussed on the episode
Think you know what it takes to keep weight off? Most people can tell you how to lose weight, but ask them what actually predicts keeping it off, and the answers get shaky fast. That’s a problem, because losing weight and maintaining weight loss are two completely different biological and behavioral games, and confusing the two is one of the biggest reasons people yo-yo.
In this episode, Holly and Jim put their listeners to the test literally. They’ve built a 20-question pop quiz covering everything from the hidden biology of metabolic adaptation to the real findings from the National Weight Control Registry, the groundbreaking study Jim co-founded three decades ago. And because so much has changed recently, they’re also tackling the question everyone’s asking: does any of this still apply in the age of GLP-1 medications?
Grab a pen (or play along in your head) and see how many you get right. Some answers might surprise you, and a few might change how you think about your own weight loss journey for good.
Discussed on the episode:
What did humans actually evolve to eat? With paleo, keto, vegan, Mediterranean, and a thousand other diets all claiming to be "the one," it's no wonder people feel whiplashed every time they walk into a grocery store. But what if the answer isn't found in the latest diet book, but in millions of years of human evolution?
Join Holly and Jim as they welcome back Harvard evolutionary biologist Dan Lieberman for a second appearance on the show. This time, Dan isn't talking exercise. He's talking food. Drawing on his new book, "Fed Up: What Evolution Reveals About Food, Diet, Health, and Eating Well," Dan explains why there's no single "evolutionary diet," why our supermarkets are a completely unprecedented environment for the human brain, and why willpower alone was never going to be enough. And because Dan doesn't just study diets, he lives them. He shares the surprisingly rough personal experiments he and his wife put themselves through in the name of research.
By the end of this episode, you'll understand exactly why eating well feels so hard in the modern world, and why that struggle has nothing to do with a lack of discipline.
Discussed on the episode:
Resources mentioned:
Most people trying to lose weight obsess over the what: what diet, what medication, what workout plan. But according to Holly and Jim, the real key to long-term success isn't found in any of those choices. It's found in a set of decisions most people never even realize they're making.
In this episode, Holly and Jim count down the 10 decisions that determine whether a weight loss journey actually sticks. Some are questions you'd expect. Others might catch you completely off guard, including the one they say most listeners will never predict is number one.
Whether you're just starting, deep into a GLP-1 medication, working to maintain weight you've already lost, or wondering if you're on the right plan at all, this countdown is built for you. So before you make your next move, find out if you've quietly been making these decisions by default or on purpose.
Discussed on the episode:
For years, the ceiling on medical weight loss was 15%, maybe 20% if you were lucky. Now a new triple-target medication is posting average results that flirt with 30% body weight loss in clinical trials, numbers once reserved for the operating room. Holly and Jim sat down to unpack what's driving these results, and found themselves asking a question neither expected to ask in their careers: how much weight loss is actually too much?
Retatrutide, the drug at the center of this episode, adds a third receptor target to the GLP-1 and GIP combination already familiar to listeners. Holly and Jim break down what this third piece brings to the table, walk through the newest published and presented trial data, and get refreshingly honest about the parts of this "medical miracle" that keep them up at night.
More weight loss isn't automatically better weight loss. As these medications get more powerful, Holly and Jim argue the field needs to catch up fast on nutrition, dosing, and what "success" even means going forward. If you've been following the GLP-1 story, this episode is the plot twist you didn't see coming.
Discussed on the episode:
From the publisher's feed
Ranked by our users in the last 21 days

11,739 Listeners

872 Listeners

1,075 Listeners

2,194 Listeners

12,682 Listeners

1,196 Listeners

776 Listeners

2,614 Listeners

9,140 Listeners

7,922 Listeners

130 Listeners

544 Listeners

414 Listeners

1,218 Listeners

173 Listeners